Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 11:33 PM
Ignite Modification Date:
2025-12-24 @ 11:33 PM
NCT ID:
NCT01107756
Eligibility Criteria:
Inclusion criteria:
* Patients willing to sign informed consent prior to entry into the study,
* Patients who have been prescribed a Taxotere based regimen,
* Patients who have not yet started with the first Taxotere treatment,
* Patients with a histological diagnosis of one of the following solid tumours: breast cancer, non-small cell lung cancer (NSCLC), ovarian cancer, prostate cancer, gastric cancer or head and neck cancer.
Exclusion criteria:
* Patients who are enrolled in another clinical study,
* Pregnant and/or breastfeeding patients, including women of childbearing potential not willing to use medically acceptable methods of contraception,
* Patients with severe liver impairment,
* Patients with severe renal function impairment,
* Patients with a known hypersensitivity to Granocyte 34 or its constituents,
* Patients with a history of severe hypersensitivity reactions to Taxotere or Polysorbate 80,
* Patients with a baseline neutrophil count of \< 1500cells/mm3,
* Patients on other drugs that are contra-indications for the use with Taxotere,
* Patients on con-current radiotherapy.
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
21 Years
Maximum Age:
75 Years
Study:
NCT01107756
Study Brief:
Protocol Section:
NCT01107756